|Positive Control||ROS1 Fusion NSCLC|
$0.00 – $855.00
In Stock & Ready to Ship
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumours have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have observed ROS1 gene rearragement events in approximately 1% of lung cancers and showed that inhibition of tumour cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.